One of the world's biggest pharmaceutical firms has signed an agreement with Cambridge's Horizon Discovery Group.
Roche has sealed a deal with Horizon which will see the two companies developing immunohistochemistry (IHC) assays, which are used in the development of new drugs. Horizon will develop and provide a type of genetic biomarker, known as NTRK, to Roche. Rearranged NTRK genes have recently emerged as promising targets for cancer therapy, and a number of novel compounds have been developed against the fusion proteins that arise from these molecular alterations.
Read more: http://bit.ly/HorizonPharma